BUSINESS |
9 Months Ended | |
|---|---|---|
Sep. 30, 2015 | ||
| Accounting Policies [Abstract] | ||
| Business Description and Basis of Presentation [Text Block] |
NOTE 1 – BUSINESS
Tonix Pharmaceuticals Holding Corp., through its wholly owned subsidiaries is a clinical-stage pharmaceutical company dedicated to the invention and development of novel pharmaceutical products that it believes have broad societal impact, since they address medical conditions that are not well served by currently available therapies and that represent large potential commercial opportunities. The consolidated financial statements include the accounts of Tonix Pharmaceuticals Holding Corp. and its wholly owned subsidiaries, Tonix Pharmaceuticals, Inc., or Tonix Sub, Krele LLC, Tonix Pharmaceuticals (Canada), Inc., Tonix Medicines, Inc., or Tonix Medicines, Tonix Pharma Holdings Limited and Tonix Pharma Limited (collectively hereafter referred to as the “Company” or “Tonix”). On May 15, 2015, Tonix Sub formed Tonix Medicines for the purpose of manufacturing and distributing pharmaceutical products in the U.S. Tonix Pharmaceuticals (Barbados) Ltd., or Tonix Barbados, a wholly owned subsidiary of Tonix Sub, was liquidated and dissolved during the nine months ended September 30, 2015. All assets and liabilities were assumed by Tonix Pharma Holdings Limited. |